Niche CDMO adds spray drying for highly potent drugs
The investment makes Idifarma one of only three companies in the world offering this type of contract development and manufacturing spray drying service.
IDIFARMA has announced new GMP spray drying capabilities which will make it one of the very few CDMO to offer spray drying technology for highly potent drugs up to Category 4 OEL/OEB.
The Spanish CDMO, which specialises in niche and highly potent products, will be one of only three companies in the world offering this type of contract development and manufacturing spray drying service with the installation of GEA Niro Mobile Minor equipment in a new dedicated area in its 4,000 sq. ft EU GMP plant.
The new equipment, which involves a significant investment for the company, will be installed and qualified in mid-2018 and will give Idifarma spray drying capacity for niche commercial products and clinical batches.
Luis Oquiñena, general manager and co-founder of Idifarma said: “We are excited to announce this new service and very proud to be at the forefront of spray drying technology. By making this investment, we will be able to provide contract manufacturing services for intermediate products, and for oral solid drugs we can continue until the finished dosage forms.
“This investment is driven by significant client demand, with the market looking for spray drying solutions as a suitable technology to improve the bioavailability of poorly soluble drugs. Idifarma now has all the ingredients to support our customers’ spray drying projects at different scales and contribute to accelerated drug development and manufacturing timelines.”
This announcement follows recent investment in both serialisation and capsule filling capabilities and strengthens Idifarma’s position as a specialised contract partner for the development and manufacturing of oral solid dosage forms, including high potency compounds and niche pharmaceuticals requiring small commercial and clinical batches.
Oquiñena added: “Our investment in new technologies reflects our continued success within the CDMO market and our intent to further grow our business with specialised capabilities. As well as new technologies we are also investing in qualified and experienced staff to deliver our services and now have 120 employees on site. As customer demand for our niche CDMO services continues to grow we fully expect both investments and staff numbers to increase steadily in the coming year.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.